September 25th, 2019

Allgenesis Biotherapeutics is pleased to announce the database lock of Day 28 data from 64 patients with pterygium that were randomized into the vehicle-controlled Phase 2a study. The initial topline data from the SURPH trial is scheduled to be available in October 2019.

“The reporting of topline data from our Phase 2a trial in patients with pterygium is a significant milestone for Allgenesis”, said Dr. Madhu Cherukury, CEO of Allgenesis. “As the current treatment options for patients with pterygium is limited to surgery, our drug potentially offers a non-invasive alternative to surgery for the treatment of the disease” added Dr. Cherukury.

Additional information on Allgenesis’ pipeline and the clinical trial for AG-86893 can be found at www.allgenesis.com and ClinicalTrials.gov (Identifier: NCT03533244). Progress of the study can be shared to potential investors and out-licensing partners pending the execution of a CDA.

About Allgenesis

Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases, AG-86893 for pterygium, and AG-67650 for wAMD.

About AG-86893

AG-86893 is a topical eye drop reformulation of a marketed oral drug, a multi-tyrosine kinase inhibitor targeting receptors of growth factors such as VEGF, PDGF and FGF. AG-86893 is being developed for the treatment of pterygium, following a 505(B)(2) pathway. Currently, there is no approved treatment for pterygium other than surgery. A clinical Phase 2a study (trial name: SURPH*) for AG-86893 is being conducted in pterygium patients in Australia with last-patient-out by end of 2019.

*SURPH = StUdy of the Response to AG-86893 in patients with Pterygium Hyperemia

About AG-73305

AG-73305 is a first-in-class molecule specifically designed for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is a single fusion protein that simultaneously binds to VEGF and integrins with high potency and specificity. During the discovery stage, AG-73305 demonstrated promising efficacy in protecting the blood-retina-barrier in a rabbit POC model and in a laser-induced CNV monkey model. AG-73305 has a desirable ocular pharmacokinetic profile and was well-tolerated in monkeys after intravitreal injection.